- Home
- DXR vs CALC Comparison
DXR vs CALC Comparison
Compare DXR & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- CALC
- Stock Information
- Founded
- DXR 1970
- CALC 2011
- Country
- DXR United States
- CALC United States
- Employees
- DXR N/A
- CALC N/A
- Industry
- DXR Medical/Dental Instruments
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- CALC Health Care
- Exchange
- DXR Nasdaq
- CALC Nasdaq
- Market Cap
- DXR 46.9M
- CALC 45.4M
- IPO Year
- DXR N/A
- CALC N/A
- Fundamental
- Price
- DXR $13.00
- CALC $3.23
- Analyst Decision
- DXR Strong Buy
- CALC Strong Buy
- Analyst Count
- DXR 1
- CALC 2
- Target Price
- DXR $25.00
- CALC $14.50
- AVG Volume (30 Days)
- DXR 6.1K
- CALC 54.6K
- Earning Date
- DXR 01-01-0001
- CALC 11-12-2025
- Dividend Yield
- DXR N/A
- CALC N/A
- EPS Growth
- DXR 3.46
- CALC N/A
- EPS
- DXR 0.36
- CALC N/A
- Revenue
- DXR $66,306.00
- CALC N/A
- Revenue This Year
- DXR N/A
- CALC N/A
- Revenue Next Year
- DXR N/A
- CALC N/A
- P/E Ratio
- DXR $35.22
- CALC N/A
- Revenue Growth
- DXR N/A
- CALC N/A
- 52 Week Low
- DXR $6.55
- CALC $1.42
- 52 Week High
- DXR $14.00
- CALC $5.65
- Technical
- Relative Strength Index (RSI)
- DXR 57.62
- CALC 52.57
- Support Level
- DXR $12.70
- CALC $3.13
- Resistance Level
- DXR $14.00
- CALC $3.33
- Average True Range (ATR)
- DXR 0.52
- CALC 0.20
- MACD
- DXR -0.13
- CALC -0.00
- Stochastic Oscillator
- DXR 50.00
- CALC 38.24
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.